Home > About Welchol
About Welchol
Sign Up for Updates
Be notified about site updates, educational opportunities, and more.
About Welchol
For patients with type 2 diabetes and/or primary hyperlipidemia who need additional A1C and LDL-C reductions, adding Welchol™ (colesevelam HCl):
- Achieves additional mean A1C reductions of up to 0.8% when added to preexisting antidiabetic (AD) monotherapy
- Achieves nearly 50% total mean LDL-C reduction when added to atorvastatin 10 mg1
- Effective without entering the bloodstream
- Provides an established safety record in the treatment of primary hyperlipidemia
- Preferred formulary status on most managed care plans2
Efficacy
Learn more about the efficacy of Welchol in type 2 diabetes and in primary hyperlipidemia.
Dosage & Administration
Learn about the dosing and administration of Welchol.
Welchol is indicated as an adjunct to diet and exercise to:
- Reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor
- Improve glycemic control in adults with type 2 diabetes mellitus
References
1. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-16.
2. Data on file. Daiichi-Sankyo, Inc., Parsippany, NJ.